Stockhub

Oxurion NV: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

21 August 2022

  • curprev 20:2220:22, 21 August 2022 >Nick 867 bytes +867 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagoni..."
Retrieved from "https://stockhub.co/research/Oxurion_NV"